About Stempeutics
Stempeutics is a company based in Bengaluru (India) founded in 2006. Stempeutics has raised $47.3 million across 13 funding rounds from investors including Manipal Group, Cipla and Max Medisupport. The company has 27 employees as of March 22, 2024. Stempeutics offers products and services including Stempeucel®, Cutisera®, Trichosera®, and Perioptisera®. Stempeutics operates in a competitive market with competitors including Mesoblast, RoosterBio, SanBio, Cellular Biomedicine Group and BrainStorm Cell, among others.
- Headquarter Bengaluru, India
- Employees 27 as on 22 Mar, 2024
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Stempeutics Research Private Limited
- Date of Incorporation 16 Jan, 2006
- Jurisdiction Bengaluru, Karnataka, India
-
Annual Revenue
$468.37 K (USD)98.1as on Mar 31, 2018
-
Net Profit
-$480.02 K (USD)84.8as on Mar 31, 2018
-
EBITDA
-$887.98 K (USD)60.9as on Mar 31, 2018
-
Total Equity Funding
$47.3 M (USD)
in 13 rounds
-
Latest Funding Round
$1.73 M (USD), Series B
Apr 15, 2021
-
Investors
Manipal Group
& 5 more
-
Employee Count
27
as on Mar 22, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Stempeutics
Stempeutics offers a comprehensive portfolio of products and services, including Stempeucel®, Cutisera®, Trichosera®, and Perioptisera®.
Stem cell therapy for treating critical limb ischemia and osteoarthritis.
Stem cell-based product for firming and moisturizing skin.
Bio-active serum to promote hair growth and reduce hair fall.
Concentrate for reducing under-eye dark circles and soothing skin.
Funding Insights of Stempeutics
Stempeutics has successfully raised a total of $47.3M across 13 strategic funding rounds. The most recent funding activity was a Series B round of $1.73 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Stempeutics
Stempeutics has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Manipal Group, Cipla and Max Medisupport.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund focused on multiple sectors
|
Locked | Locked | Locked | |
|
Provides comprehensive business management software solutions for hospitals.
|
Locked | Locked | Locked | |
|
Education, healthcare, insurance, and research services are provided globally.
|
Locked | Locked | Locked |
Investor details for Stempeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Stempeutics
Investment portfolio details for Stempeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Stempeutics
Detailed financials for Stempeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Stempeutics Comparisons
Peer comparison for Stempeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Stempeutics
Stempeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Mesoblast, RoosterBio, SanBio, Cellular Biomedicine Group and BrainStorm Cell, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Biotherapeutics derived from proprietary adult stem cell-based technologies
|
|
| Locked | Locked | Locked |
Developer of human mesenchymal stem cells and extracellular vesicles
|
|
| Locked | Locked | Locked |
Regenerative cell medicines for neurological disorders are developed.
|
|
| Locked | Locked | Locked |
Cellular therapeutics are developed for cancer, orthopaedics, and COPD.
|
|
| Locked | Locked | Locked |
Developer ofstem cell therapies for the treatment of neurodegenerative diseases such as ALS, MS, PD
|
|
| Locked | Locked | Locked |
Mesenchymal stem cells are developed for therapeutics using proprietary methods.
|
Detailed competitors of Stempeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Stempeutics
Complete news archive for Stempeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stempeutics
Stempeutics was founded in 2006 and raised its 1st funding round 1 year after it was founded.
Stempeutics is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
Stempeutics is a funded company, having raised a total of $47.3M across 13 funding rounds to date.
As of Mar 22, 2024, the latest employee count at Stempeutics is 27.
Annual revenue of Stempeutics is $468.37K as on Mar 31, 2018.
Stempeutics, a joint venture between Cipla and Manipal develops stem-cell based products. Its lead product Stempeucel is an off-the-shelf product comprised of adult allogeneic mesenchymal stem cells derived from multiple bone marrow donors. In 2016 DCGI (Indian FDA) granted its limited approval for the treatment of CLI patients due to Buergers disease. It is also in clinical trials for critical limb ischemia, osteoarthritis, liver cirrhosis, acute myocardial infraction and ICM (Ischemic Cardiomyopathy) in India and Malaysia. Besides, it also developed Stempeutron, a point-of-care device for automated isolation of autologous stromal vascular fraction (SVF) cells from adipose tissue. It also has a line of OTC stem cell based cosmetic products called Stempeucare.
Stempeutics's top competitors include RoosterBio, Mesoblast and SanBio.
Stempeutics offers Stempeucel®, Cutisera®, Trichosera®, and Perioptisera®.
Stempeutics has 6 investors. Key investors include Manipal Group, Cipla, Max Medisupport, MNI Ventures, and Meditab Specialities.
The valuation of Stempeutics is $53.47M as of Apr 2021.